These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19104028)

  • 1. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tolerability of oseltamivir combined with probenecid.
    Holodniy M; Penzak SR; Straight TM; Davey RT; Lee KK; Goetz MB; Raisch DW; Cunningham F; Lin ET; Olivo N; Deyton LR
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3013-21. PubMed ID: 18559644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
    Kamal MA; Van Wart SA; Rayner CR; Subramoney V; Reynolds DK; Bulik CC; Smith PF; Bhavnani SM; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3470-7. PubMed ID: 23669384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
    Reddy MB; Yang KH; Rao G; Rayner CR; Nie J; Pamulapati C; Marathe BM; Forrest A; Govorkova EA
    PLoS One; 2015; 10(10):e0138069. PubMed ID: 26460484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.
    Taylor WR; Thinh BN; Anh GT; Horby P; Wertheim H; Lindegardh N; de Jong MD; Stepniewska K; Hanh TT; Hien ND; Bien NM; Chau NQ; Fox A; Ngoc NM; Crusat M; Farrar JJ; White NJ; Ha NH; Lien TT; Trung NV; Day N; Binh NG
    PLoS One; 2008; 3(10):e3410. PubMed ID: 18923671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.
    Jhee SS; Yen M; Ereshefsky L; Leibowitz M; Schulte M; Kaeser B; Boak L; Patel A; Hoffmann G; Prinssen EP; Rayner CR
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3687-93. PubMed ID: 18676886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
    Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.
    Kongpatanakul S; Chatsiricharoenkul S; Panich U; Sathirakul K; Pongnarin P; Sangvanich P
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):654-62. PubMed ID: 19049700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.
    Kamal MA; Acosta EP; Kimberlin DW; Gibiansky L; Jester P; Niranjan V; Rath B; Clinch B; Sánchez PJ; Ampofo K; Whitley R; Rayner CR
    Clin Pharmacol Ther; 2014 Sep; 96(3):380-9. PubMed ID: 24865390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of oseltamivir when coadministered with probenecid.
    Rayner CR; Chanu P; Gieschke R; Boak LM; Jonsson EN
    J Clin Pharmacol; 2008 Aug; 48(8):935-47. PubMed ID: 18524996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.
    Jittamala P; Pukrittayakamee S; Tarning J; Lindegardh N; Hanpithakpong W; Taylor WR; Lawpoolsri S; Charunwattana P; Panapipat S; White NJ; Day NP
    Antimicrob Agents Chemother; 2014; 58(3):1615-21. PubMed ID: 24366750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
    Kamal MA; Brennan BJ; Subramoney V; Lien YT; Morcos PN; Frey N; Rayner CR
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):326-36. PubMed ID: 27137141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of oseltamivir at standard and high dosages.
    Dutkowski R; Smith JR; Davies BE
    Int J Antimicrob Agents; 2010 May; 35(5):461-7. PubMed ID: 20189775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
    Deng R; She G; Maia M; Lim JJ; Peck MC; McBride JM; Kulkarni P; Horn P; Castro A; Newton E; Tavel JA; Hanley WD
    J Clin Pharmacol; 2020 Nov; 60(11):1509-1518. PubMed ID: 32621543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers.
    Jang K; Kim MK; Oh J; Lee S; Cho JY; Yu KS; Choi TK; Lee SH; Lim KS
    Drug Des Devel Ther; 2017; 11():705-711. PubMed ID: 28331290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).
    Thorne-Humphrey LM; Goralski KB; Slayter KL; Hatchette TF; Johnston BL; McNeil SA;
    J Antimicrob Chemother; 2011 Sep; 66(9):2083-91. PubMed ID: 21700623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.
    Schentag JJ; Hill G; Chu T; Rayner CR
    J Clin Pharmacol; 2007 Jun; 47(6):689-96. PubMed ID: 17456583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
    Brennan BJ; Davies B; Cirrincione-Dall G; Morcos PN; Beryozkina A; Chappey C; Aceves Baldó P; Lennon-Chrimes S; Rayner CR
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4729-37. PubMed ID: 22733065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.